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Abstract
Monoclonal antibodies (mAbs) and proteins containing antibody domains are the most prevalent class of biotherapeutics in
diverse indication areas. Today, established techniques such as immunization or phage display allow for an efficient
generation of new mAbs. Besides functional properties, the stability of future therapeutic mAbs is a key selection criterion
which is essential for the development of a drug candidate into a marketed product. Therapeutic proteins may degrade via
asparagine (Asn) deamidation and aspartate (Asp) isomerization, but the factors responsible for such degradation remain
poorly understood. We studied the structural properties of a large, uniform dataset of Asn and Asp residues in the variable
domains of antibodies. Their structural parameters were correlated with the degradation propensities measured by mass
spectrometry. We show that degradation hotspots can be characterized by their conformational flexibility, the size of the C-
terminally flanking amino acid residue, and secondary structural parameters. From these results we derive an accurate in
silico prediction method for the degradation propensity of both Asn and Asp residues in the complementarity-determining
regions (CDRs) of mAbs.
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Introduction
Monoclonal antibodies (mAbs) and new antibody domain-based
molecules constitute the majority of protein therapeutics under
clinical investigation [1,2] for severe malignancies such as cancer,
viral and inflammatory diseases. mAbs are potent in a diverse
range of therapeutic indications, and are readily generated against
promising new targets. The specificity of mAbs is determined by
sequences in the CDRs located in the variable Fv domain. The
process of selecting the clinical candidate mAb typically starts with
large-scale screening for functional properties. Screening is
followed by detailed in vitro profiling of multiple mAbs to identify
candidates that fulfill all desired functional criteria. To ensure
optimal technical development and in vivo stability, potentially
instable mAbs have to be identified and excluded during the lead
selection process.
During manufacturing, storage and in vivo, therapeutic antibod-
ies are at risk for degradation via a number of pathways (reviewed
by [3]). Amongst the most frequently occurring degradation
reactions in proteins are the chemical degradation of Asn [4] and
Asp residues [5,6]. While these reactions may be kept under
control by appropriate storage and formulation conditions [7–10]
of the final drug substance and drug product, degradation during
fermentation, downstream-processing, and in vivo can often not be
controlled sufficiently. If Asn and Asp residues are involved in
antigen recognition, their chemical alteration can lead to severe
loss of potency [11–15]. In several cases, these degradation events
were reported to hamper long-term mAb functionality
[11,12,14,16–19]. In vivo, protein degradation events are described
in connection with protein ageing [20–26], with cancer by
triggering apoptosis [27–29] or with severe effects on other
biological functions, e. g. stability decrease of human lens betaA3-
crystallin, abnormal MAPK signaling, the alteration of potential
beta-secretase efficacy and specificity in the course of Abeta
generation, or increase of lysozyme lytic activity against bacterial
cells [30–37]. The identification of degradation-prone drug
candidates is ideally done early in the drug development process
to either adjust the manufacturing and formulation process
accordingly or to re-engineer a problematic candidate to remove
such hotspots [38].
Asn and Asp residues share a degradation pathway that
proceeds via the formation of a cyclic succinimide intermediate
(Figure 1) [4,6,39]. Succinimide results from deamidation of Asn
or dehydration of Asp by nucleophilic attack of the backbone
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nitrogen of the succeeding amino acid on the Asn/Asp side chain
c-carbonyl group. The metastable cyclic imide can hydrolyze at
either one of its two carbonyl groups to form aspartyl or iso-
aspartyl linkages in different ratios, depending on hydrolysis
conditions and conformational restraints [4,6,18,25,40,41]. In
addition, alternative degradation mechanisms for Asn were
proposed [11] such as nucleophilic attack by the backbone
carbonyl oxygen to form a cyclic isoimide [6,42,43] or direct
hydrolysis of Asn to Asp [44,45] (Figure 1). Several analytical
methods, mostly charge-sensitive methods such as ion exchange
chromatography or isoelectric focusing, were described to detect
either of the degradation products, i.e. succinimide, Asp or isoAsp
[14,46–48]. Most suitable for the quantification and the localiza-
tion of degradation sites in proteins is the analysis via liquid
chromatography tandem mass spectrometry (LC-MS/MS)
[13,14,16,19,43,49–56].
Diverse parameters were proposed which may influence the
degradation propensity of Asn and Asp residues, e.g. the primary
sequence [4,6,21,39,45,57–62], the solvent dielectric constant,
temperature, and the pH, mostly in the peptide [58,59,63–65], but
also in the protein context [8,11,18,66]. Already in the 1980s,
several structural requirements were suggested as principal
determinants for protein deamidation [6,67] which have later
been confirmed and extended [16,40,42,43,45,57,68–70].
Despite accumulated knowledge about the degradation mech-
anism and its structural requirements, the reliable prediction of
deamidation and isomerization in mAbs remains an unresolved
issue. In the early stages of drug discovery, the amino acid
sequence is often known for a large number of lead candidates, but
the protein amounts available for in vitro stability testing are often
limited and the necessary mass spectrometry assays are labor
intensive and time consuming. Thus, the possibility to reliably
predict Asp and Asn hotspots without the need for experiments is
key to the rapid identification of stable Fv sequences early in the
discovery phase.
To shed light on the complex interplay of several parameters
potentially leading to chemical degradation, we generated a
uniform experimental data set of site-specific degradation events
before and after ‘‘stress’’ treatment in 37 mAbs by mass
spectrometry. These in vitro data combined with structural
parameters derived from homology models were used to study
the quantitative contribution of structural parameters in the
degradation pathway, and to develop an in silico approach for the
identification and selection of chemically stable mAbs during the
clinical candidate generation process.
Results
Experimental survey of antibody degradation sites and
rates
In order to determine the driving factors for Asn and Asp
degradation sites in the Fv regions of mAbs, analytical, structural,
and computational methods were combined. A collection of 37
different therapeutic IgG1, IgG2 and IgG4 mAbs (in-house as well
as marketed products) was investigated (Table 1, Materials and
Methods). These antibodies were subjected to forced degradation
(‘‘stress’’) at a typical formulation pH of 6.0 at 40uC for 2 weeks
(Material and Methods), and subsequently analyzed for degrada-
tion events by mass spectrometric analysis after tryptic digestion.
Thereby the affected residues were identified and the amount of
Figure 1. Asparagine and Aspartate degradation pathways. Deamidation of asparagine or dehydration of aspartic acid occurs by nucleophilic
attack of the a-amino group of the C-terminally flanking amino acid. This leads to formation of a metastable succinimide (cyclic imide) intermediate,
which hydrolyzes to a mixture of aspartyl and iso-aspartyl linkages. Alternatively, nucleophilic attack by the backbone carbonyl oxygen results in a
cyclic isoimide intermediate, yielding only aspartyl residues after hydrolysis independent of the point of attack of the incoming water molecule.
Asparagine residues can deamidate to Asp by direct water-assisted hydrolysis. Standard amino acids (Asn, Asp) are outlined with black boxes.
doi:10.1371/journal.pone.0100736.g001
Structure-Based Asn and Asp Degradation Prediction
PLOS ONE | www.plosone.org 2 June 2014 | Volume 9 | Issue 6 | e100736
modification in stressed and corresponding reference samples was
quantified (Materials and Methods). Modifications already present
in unstressed samples, for instance due to poor stability at
physiological pH during fermentation or induced during biopro-
cessing, were also detected. To avoid further modification and to
stabilize the cyclic imide intermediate, the pH was maintained at
6.0 during peptide map sample preparation [54,71]. The
evaluation of the entire set of 74 LC-MS/MS peptide mapping
experiments from 37 stressed and corresponding reference samples
enabled us to detect all possible products of Asn and Asp
degradation, i.e. the succinimide intermediate, iso-Asp, and Asp
(example in Figure S1). Out of all 559 Asn and Asp residues in the
Fv regions of the 37 mAbs, 60 residues (11%) exhibit quantifiable
amounts of modification. We sub-classified these into 21 hotspots
(Table 1), 14 weak spots (Table S1), and 24 reactive spots (Table
S2). The term hotspot corresponds to $3%, weak spot to $1 and
,3%, and reactive spot to ,1% modification in the stressed
samples. In the data set used for statistical evaluation, only
hotspots and non-hotspots were considered. In order to achieve a
reliable, unambiguous dataset, reactive spots and weak spots, as
well as hotspots with unclear assignment or within an Fv N-
glycosylation site were excluded from the dataset.
Degradation sites are exclusively located in CDRs
Strikingly, all degradation hotspots are located in the CDR
loops (Table 1). Thus, the CH1/CL domains and the Fv framework
represent a stable scaffold. Most hotspots are located in the light
chain CDR 1 and the heavy chain CDR 3, whereas in our dataset
heavy chain CDR 1 does not contain any hotspot. In summary, 15
out of 37 analyzed mAbs contain at least one Asn or Asp hotspot
in one of the CDRs.
It was shown in previous studies that the amino acid residue
succeeding Asn and Asp influences the rate of succinimide
formation in proteins [45,57]. So far, eight different sequence
motifs involved in chemical degradation within Fv regions of
therapeutic antibodies have been described (Asn succeeded by
Gly, Ser, or Thr, and Asp succeeded by Gly, Ser, Thr, Asp, or His)
[11–18,72–79]. In accordance with previous observations, Asn-
Gly and Asp-Gly motifs are by far the motifs most prone to
modification in our data set, accounting for 67 and 36% of
hotspots observed, respectively (Figure 2). All described sequence
motifs except Asp-Thr and Asp-His were observed as degradation
sites in the CDRs of our antibody collection. In addition, chemical
degradation was detected at an Asn-Asn motif in mAb14 (Table 1).
Degradation at this sequence motif has so far not been described in
antibody CDRs, but in other proteins [45].
To assess the relevance of our therapeutic mAb collection in
relation to naturally occurring antibodies, the frequency of the
known Asn and Asp degradation sequence motifs (NG, NN, NS,
NT, DG, DS, DT, DD, DH) was compared between the CDRs of
our mAb collection (combined Kabat and Chothia definitions
[80]) and 16286 naturally occurring human mAb sequences (9990
V-D-J and 6296 V-J sequences) from the international ImMuno-
GeneTics (IMGT) information system’s monoclonal antibody
database (www.IMGT.org). Despite the enormous difference in
Table 1. Experimental Asn and Asp hotspot collection.
mAb modifi-cation % modified (stressed) % modified (un-stressed) motif location
mAb22 iD+suc 39 14 DG HC CDR 3
Omalizumab [12] iD+suc 31 3 DG LC CDR 1
mAb2 iD+suc 26 3 DS LC CDR 2
Trastuzumab [11,54] dea*+suc 24 11 NT LC CDR 1
Trastuzumab [11,54] iD+suc 22 7 DG HC CDR 3
mAb14 dea 22 n.a. NS LC CDR 3
mAb1` dea+suc 17 5 NT HC CDR 3
mAb22 iD+suc 12 6 DG LC CDR 2
mAb13 iD+suc 10 n.a. DG HC CDR 3
Nimotuzumab iD+suc 9 2 DS HC CDR 3
mAb26 dea 8 3 NG LC CDR 1
Nimotuzumab` dea#+suc# 8 5 ? LC CDR 1
mAb32 dea 6 5 NS HC CDR 2
Infliximab dea 6 2 NS HC CDR 2
Natalizumab dea+suc 5 3 NG HC CDR 2
Trastuzumab [11,54] dea+suc 5 4 NG HC CDR 2
mAb17 dea+suc 4 1 NS LC CDR 1
mAb14 suc 4 0 NN LC CDR 1
mAb11 suc 4 2 NT LC CDR 1
mab48 dea+suc 3 2 NG HC CDR 2
mAb2 iD+suc 3 n.a. DS HC CDR 3
*only Asp as deamidation species.
`excluded from hotspot data set because of interaction with a CDR glycosylation site which is not represented by the homology models.
#proof of modification site impossible with available methods (tryptic peptide, AspN peptide, CID fragmentation, HCD fragmentation), thus excluded from the hotspot
data set.
Main modifications are written in bold. iD = isomerization, suc = succinimide, dea = deamidation, n.a.: not assessed.
doi:10.1371/journal.pone.0100736.t001
Structure-Based Asn and Asp Degradation Prediction
PLOS ONE | www.plosone.org 3 June 2014 | Volume 9 | Issue 6 | e100736
size of the compared datasets, the frequency at which Asn and Asp
motifs occur, is distributed comparatively equally and shows that
the sequence composition of the investigated antibody molecules
contains low bias (Figure 2). The only exception is the NT motif
that is found twice as frequently in therapeutic mAbs than in
IMGT. Obviously, the most degradation-prone Asn-Gly and Asp-
Gly motifs are comparatively infrequent.
Analysis of degradation site structure
The structural environment of Asn and Asp hotspots and non-
hotspots in the antibodies’ Fv fragments was characterized by a set
of 20 parameters with a putative role in the degradation
mechanism. Homology models of Fv fragments were generated
by a state-of-the art homology modeling software (Materials and
Methods). Parameters were extracted from these homology models
by an automated procedure (Materials and Methods). Generally,
the high homology to template structures typically results in
precise homology models of framework and short CDR regions.
However, modeling of long CDR loops is prone to large modeling
uncertainties, possibly due to the high inherent flexibility of such
loops [81–84]. Therefore, all CDRs were subjected to an
additional loop modeling procedure [85] (Materials and Methods),
yielding a five-membered homology model ensemble. Like this,
additional information on different possible CDR conformations
was captured (Figure S2), without the necessity of computationally
demanding molecular dynamics simulations. Moreover, bias in
homology models generated from templates with bound antigen is
removed by the loop refinement procedure which models loops
using experimental loop structures from a loop database, followed
by energy minimization. The correlation between structural
parameters and in vitro degradation was investigated by machine-
learning algorithms. Statistical validation of the predicting model
shows promising accuracy and low mis-prediction compared to
sequence motif-based prediction.
A set of 20 parameters describes the structural
environment of Asn and Asp residues
As the discrimination of both Asn/Asp degradation hotspots
and stable Asn/Asp residues only based on primary sequence is
prone to massive over-prediction [57], a set of 20 structural
parameters described below was defined to reflect the 3D
environment of these amino acids. They were chosen on the basis
of their putative role in the degradation mechanism (Figure 1,
Figure 3, Table S1) and were computationally extracted from the
homology model ensembles.
A prerequisite for cyclic imide formation is the leaving tendency
of the hydroxyl or the amino group of the Asp or Asn side chain,
respectively. To estimate this tendency, the number of hydrogen
bonds to the side chain oxygen atoms, or the side chain nitrogen
atom was counted. For succinimide formation to occur, the
carboxyl group of the Asp side chain must be protonated [39,86].
The probable protonation state was obtained by calculating the
structure-dependent Asp pKa values using the PROPKA algo-
rithm (SI Materials and Methods) [87]. Accessibility and high
nucleophilicity of the succeeding backbone nitrogen are other
potential prerequisites for succinimide formation (Figure 1).
Therefore, the succeeding backbone nitrogen’s solvent accessible
surface area was calculated and the number of hydrogen bonds
was counted.
The transition state of the succinimide formation reaction
requires the Asp or Asn head group to approach the backbone
nitrogen of the succeeding residue. Transition state-like confor-
mation was probed by measuring the distance of the side chain Cc-
atom to the Nn+1-atom (Figs. 1, 3 [67]), the side chain dihedral
angle x1, and the dihedral angle CGONC that was defined as the
angle between the atoms Cc, O, Nn+1, and C. Additionally, the
solvent-accessible surface area of each Asp or Asn was calculated.
It was shown that the residue succeeding an Asn or Asp influences
the rate of succinimide formation [4,6,21,34,39,57,58,60]. Hence,
Figure 2. Occurrence of Asn and Asp amino acid motifs in the CDRs of a therapeutic mAb collection and a set of naturally occurring
antibodies (IMGT). Black triangles show percentages of hotspots within Asn and Asp motifs of the experimental collection of 37 mAbs. Bars
represent percentages of depicted sequence motifs among all Asn or Asp residues in only CDR regions. Percentages shown as filled bars represent
the non-redundant collection of the 37 analytically assessed therapeutic mAbs, bars striped in light grey belong to a collection of 9990 V-D-J- and
6296 V-J regions of naturally occurring antibodies from the IMGT database. (A) Asn sequence motifs, (B) Asp sequence motifs.
doi:10.1371/journal.pone.0100736.g002
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the successor amino acid size is recorded, as well as the backbone
dihedral angles Q (C’n-1-N-C
a-C’) and y (N-Ca-C’-Nn+1) which
provide information about the local structural conformation and
thus the potential accessibility of the transition state.
Further parameters describe the broader structural environ-
ment. The root mean square deviation (RMSD) of the Asn/Asp
residues’ Ca-atoms in the homology model ensemble reflects
structural diversity within the ensemble and is seen as an
indication of possible conformational flexibility. The secondary
structure the residue is embedded in (helix, sheet, turn, or coil)
[40,68], and the distance to the next different N- and C-terminal
secondary structure element [57] are included as additional
parameters. If a residue is located in a coil secondary structure, its
position within the coil (margin or center) was annotated
(Materials and Methods). To quantify the ‘‘bend’’ of a coil tip,
the distance between the Ca-atoms of the n-1 and the n+1 residues
was measured. Finally, the location within the Fv fragment (CDRs
or framework) was attributed to each residue.
Machine learning
Nine different machine learning methods were tested with the
goal to find the optimal classifier for distinction between hotspots
and non-hotspots in the Fv region. Our data set consisting of 185
models (3765 models) contains in the case of Asn 55 hotspots and
940 non-hotspots, in the case of Asp 40 hotspots and 1425 non-
hotspots, and was used for statistical analysis. Training of the
classifiers was performed separately for Asn and Asp with a
random 75% training dataset (always keeping the 5-membered
ensembles together), excluding terminal residues as well as weak
spots and reactive spots to avoid misleading classification.
Bayesian classification, recursive partitioning, support vector
machines, random forests, regularized discriminant analyses, and
neuronal networks were tested in 40 repeats of random training set
assignments (Monte Carlo cross validation), using all 20 param-
eters (SI Materials and Methods). Monte Carlo cross validation is
described as a mathematically stringent validation approach in
cases where no large, independent training and validation data sets
are available [88,89]. Asn and Asp classifications were separately
dealt with because Asn degradation could follow different
mechanisms [6,42–45], (Figure 1), which led to an improved
classification scheme. A residue counts as a predicted hotspot if at
least one member of the five-membered ensemble was classified as
such. To choose the optimal classifier out of the tested
classification models, we used a receiver operating characteristic
(ROC) analysis that is commonly applied to illustrate the
performance of binary classification systems (SI Materials and
Methods). Weighting a high true-positive rate as the most
important criterion, the Pipeline Pilot implementation of a
single-tree lookahead-enabled recursive partitioning algorithm
[90] was chosen as the most suitable classifier and optimized for
prediction purposes (Figure 4, Figure 5, SI Materials and
Methods). The decision trees are shown in Figure 6.
After forty runs of test set validation against the model trained
with randomized 75% training sets, an average of 0.5 out of 8 Asp-
hotspots were not recognized, whereas an average of 6.6 out of
Figure 3. Parameters characterizing Asn and Asp residues in a structural environment outlined at an exemplary Asp residue.
Parameters describing the carboxyl/amino group leaving tendency, the transition state accessibility, the Nn+1 nucleophilicity, and the structural
environment are depicted in pink, light blue, purple, and dark blue, respectively. Parameter names are used as in Table S1.
doi:10.1371/journal.pone.0100736.g003
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285 Asp non-hotspots were assigned false-positively. This corre-
sponds to a TPR of 0.94, being the number of true positives (7.5)
divided by the number of positives (8), and a FPR of 0.02, defined
as the number of false positives (6.6) divided by the number of
negatives (285) (Figure 4 A,C). In the case of Asn, an average of 0.6
out of 11 Asn-hotspots was assigned as false-negative (TPR = 0.95)
and 8.1 out 188 non-hotspots were obtained as false-positives
(FPR = 0.04) (Figure 4 B,D). This is a significant improvement to
prediction based on solely primary sequence information, which
led to a strong over-prediction in our dataset (Asp TPR = 1.0,
FPR = 0.31; Asn TPR = 0.91, FPR = 0.41).
Asp and Asn degradation propensity depends on residue
flexibility, successor size, and secondary structure
In the case of Asp, the dataset consists of only 2.7% hotspots
that need to be distinguished from the non-hotspot Asp residues.
The first two decision tree splits can separate 93% of all non-
hotspots (Figure 6 A). Non-hotspots are either inflexible or are
succeeded by a large C-terminal amino acid. The remaining Asps
to be classified show a high degree of conformational variability in
the model ensembles and are succeeded by a small amino acid
(Gly, Ala, Ser, Cys, or Asp). Of these, the first and largest Asp
hotspot class is characterized by very high conformational
Figure 4. ROC plots for comparison of 3D classifiers to sequence-based prediction shows significant decrease of false-positive
rates. Evaluation of different statistical methods is compared with only sequence-based prediction. For statistical classification methods, average
numbers of false-positive and false-negative Asn/Asp residues are results of 40 rounds of Monte Carlo cross validation. TPR (true positive rate) =
number of true positives divided by number of positives. FPR (false positive rate) = number of false positives divided by number of negatives. Tree,
rpart, PP (Pipeline Pilot) tree, and RandomForest are recursive partitioning algorithms; svm, ksvm are support vector machine algorithms; rda is a
regularized discriminant analysis algorithm; nnet is a neural network; sequence-based corresponds to prediction based on sequence motifs NG, NS,
NT, and DG, DS, DT, DD, DH. The Pipeline Pilot tree, shown as a yellow circle, was selected as prediction algorithm, at pruning level 4. A: Asp model; B:
Asn model. Panels C and D show a zoom view of the panels A and B, respectively. The numerical values shown in these graphs can be found in Table
S3.
doi:10.1371/journal.pone.0100736.g004
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variability (RMSD.0.485) and Asp, Cys, Ser, Ala or Gly as a
successor. It contains 5 hotspots (5 members each) as well as 2 non-
hotspot Asp residues (5 members each).
At the next node, hotspot class 2 is split off. Its 3 members (1
with 5 homology model members, 1 with 2, and 1 with 1 member
only) are characterized by moderate conformational variability
(RMSD between 0.145 and 0.485), are followed by either Asp,
Cys, Ser, Ala or Gly, and show a change in C-terminal secondary
structure within a stretch of less than 3 amino acids.
Hotspot class 3 represents an Asp-Gly motif with moderate
conformational variability (RMSD 0.145–0.485) and a change in
C-terminal secondary structure within more than 3 residues. It
contains 2 hotspots (1 with 4 homology model members, and 1
with 3 members) and 1 false-positive Asp (5 members).
For Asn degradation hotspot classification, the main criteria are
the size of the carboxy-terminal amino acid and conformational
variability (Figure 6 B). Compared to the Asp dataset, there are
twice as many Asn hotspots in relation to non-hotspots, which
correspond to 5.5%. Also here, the first two decision tree splits can
separate the bulk of non-hotspots (72%). Non-hotspots are
succeeded by a big carboxy-terminal amino acid or are inflexible.
The next split criterion is the successor size and leads to 2
branches, containing Asn residues with a successor size less or
greater than 102.7 Å2. The latter is further categorized by the
CDR loop location. Thus, the first Asn hotspot class contains
residues in CDR loop 1, is characterized by carboxy-terminal
residues such as Asp, Pro, Thr, or Asn, and is not inflexible
(RMSD.0.01). It contains 3 hotspot members (5 homology model
members each).
The residues with a successor size less than 102.7 Å2 are further
classified by their backbone dihedral angle phi. Asn residues
followed by Gly, Ala, Ser, or Cys (,102.7 Å2) that are not
inflexible (RMSD.0.01) and whose phi angle is smaller than 2
75.2 degrees constitute the second and largest hotspot class 2. It
contains 6 hotspot members (4 with 5 homology model members,
1 with 4, and 1 with 2 members), as well as 4 false-positives (1 with
5 homology model members, 2 with 3, and 1 with 1 member).
Hotspot class 3 is defined by the same flexibility and successor
characteristics as class 2 but its 4 members (2 with 5 homology
model members, 1 with 3, and 1 with 1 member only) feature a phi
angle greater than 275.2 degrees, high solvent exposure (SASA.
89.4 Å2) and a change in amino-terminal secondary structure
within a stretch of more than 3 amino acids. Two non-hotspot Asn
residues (1 and 2 homology model members) are also part of this
class.
Discussion
Spontaneous degradation of Asn and Asp residues in therapeu-
tic proteins can occur during production, storage, and in vivo. In
case of involvement in target binding, the formation of the
degradation products succinimide, isoAsp, and Asp embedded in
the CDRs can lead to loss of function or potency. The aim of this
study was to gain insights into the structural basis of these
degradation processes and thus allow for selection of chemically
stable antibody variable domains.
Due to known limitations of sequence-based predictions of the
propensity of Asn and Asp degradation, an in silico prediction tool
was established to facilitate selection of stable antibody candidates.
To this end we first obtained a uniform data set that contains
residue-specific quantitative data on antibody degradation prod-
ucts. Where available, these detected modifications are in
accordance with known hotspot information from published data
[11,12,54,91]. The pH was kept constant at 6.0 during forced
degradation and sample preparation to detect the succinimide
Figure 5. ROC plot for comparison of different pruning levels of decision trees. Decision trees were pruned automatically as implemented
in Pipeline Pilot. Average numbers of false-positive and false-negative Asn/Asp residues are results of 40 rounds of Monte Carlo cross validation. TPR
(true positive rate) = number of true positives divided by number of positives. FPR (false positive rate) = number of false positives divided by
number of negatives. Trees 1-3 and 5-6 are shown as spheres, tree 4 as a black triangle. Tree 1 is the un-pruned tree model. Tree 4 was selected for
prediction.
doi:10.1371/journal.pone.0100736.g005
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intermediate that quickly hydrolyzes at alkaline pH, Asp
isomerization, which occurs mainly at slightly acidic pH, and
Asn deamidation without method-induced deamidation events.
Usually, a mixture of Asp and iso-Asp is obtained in variable
ratios after succinimide hydrolysis [4,59,63] which is the case for
the majority of the deamidation events in our study. The
occurrence of only one product in the published Asn degradation
hotspot of Trastuzumab [11], which was shown to be Asp,
supports a succinimide-independent degradation pathway – either
via an alternative nucleophilic attack mechanism resulting in
isoimide [42] or via direct Asn side chain hydrolysis [44] (Figure 1).
Several approaches to predict labile Asp and Asn residues from
the sequence context or experimental X-ray structures were
proposed [6,16,40,42,43,45,57,67–70]. A tool for prediction of
Asn deamidation but not Asp isomerization or succinimide
formation in proteins was presented by Robinson & Robinson in
2001 [57]. The authors used reported deamidation rates of 198
Asn residues in 23 different proteins and 70 Asn residues in 61
human hemoglobin variants that were observed under a wide
variety of experimental conditions. The main differences to our
study are that (i) the prediction is only applicable for Asn, (ii) the
hotspot collection – hence the basis for prediction – has a
heterogeneous experimental background, (iii) the 3D information
stems from experimental X-ray structures, not from homology
models, (iv) for general users the prediction is possible for proteins
with entries in the PDB until 2001, and (v) it requires an
experimental structure for its application to new proteins. In
comparison, the model proposed in our study is adapted to the
variable region of therapeutic antibodies, and relies exclusively on
in silico calculations, bypassing the need for experimental X-ray
structures. The only prerequisites are (i) an antibody Fv domain
sequence, (ii) a homology modeling tool, (iii) a molecular
visualization software such as PyMol, and (iv), the statistical model
presented in this work. The reduction of falsely assigned hotspots
(average 2.3% for Asp, 4.3% for Asn) compared to sequence-only
based prediction (31% for Asp, 43% for Asn) is reliable enough to
employ this prediction during lead candidate selection. The cause
for the described false-positives and also the false-negatives (6.3%
Figure 6. Final Aspartate (A) and asparagine (B) decision trees. The outline of nodes and leaves is colored by the weighted majority of the
class that is present (red: hotspots, green: non-hotspots). Filling levels of the bars on the right hand side of each node/leaf refer to the fraction of the
data set. The fraction of each class at a node/leaf is shown by the colored fraction of the circle. The number of members of each node/leaf is indicated
above.
doi:10.1371/journal.pone.0100736.g006
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Asp, 5.2% Asn) is the relatively small number of hotspots (8 Asp,
11 Asn) compared to non-hotspots (285 Asp, 188 Asn). Classifi-
cation with only residues embedded in the CDR loop led to less
predictive statistical values (not shown).
The best-performing predictor for this dataset is the Pipeline
Pilot implementation of a lookahead-enabled single recursive
partitioning tree. Partitioning trees provide split criteria in the
order of their ability to split the dataset into hotspot and non-
hotspot containing subsets. Thus, parameters utilized in the first
nodes are those with a high discriminative power. Parameters
which do not contribute to data splitting, either due to a lack of
significance or due to noise, are omitted automatically.
The work presented here resulted in a tool to predict sites of
antibody degradation and reveals the main characteristics that
distinguish unstable and stable Asn and Asp amino acids in the
variable region of mAbs: Asn and Asp residues with high flexibility
and a small successor are prone to degradation. They can be
further characterized by secondary structural elements. Interest-
ingly, parameters most promptly describing the reaction mecha-
nism (Figure 1) such as the distance between the C atom and
backbone nitrogen atom of the C-terminal amino acid, the Asp
pKa value, or the side-chain dihedral angle x1, were not relevant
for classification.
The specificity of the prediction algorithm for antibodies can
help to more efficiently pre-select mAbs in the process of finding
the most stable, and simultaneously most potent clinical candidate
molecule that is brought into further development, and into the
clinic. By applying the algorithm, long-term and in vivo stability can
be predicted, avoiding late stage failure. Filling the existing data set
with more case studies representing the succinimide-independent
Asn degradation pathway would probably further explain the
structural prerequisites for this alternative mechanism. An
adjustment to new molecule formats will be the next step in the
future. With an expansion of the acquired knowledge to other
protein classes, a broader application could be an interesting step
ahead, providing a more general understanding of protein
degradation mechanisms, independent of the protein class.
Materials and Methods
mAb origin
The marketed products used in this study include Avastin
(Bevacizumab, Genentech/Roche); CYT387 (Nimotuzumab,
Oncoscience, Ch.B.: 911017W002); Erbitux (Cetuximab, Bristol-
Myers Squibb and Eli Lilly and Company, Lot: 7666001);
Herceptin (Trastuzumab, RO-45-2317/000, Lot. HER401-4,
Genentech); Humira (Adalimumab, Abbott, Ch.B.:
90054XD10); Prolia (Denosumab, Amgen, Ch.B.: 1021509);
Raptiva (Efalizumab, Genentech, Merck Serono, Lot:
Y11A6845); Remicade (Infliximab, Centocor, Ch.B.:
0RMA66104); Simulect (Basiliximab, Novartis, Ch.B.: S0014);
Synagis (Pavilizumab, MedImmune, Lot.: 122-389-12); Tysabri
(Natalizumab, Biogen Idec and Elan, LotA: 080475); Vectibix
(Panitumumab, Amgen, Ch.B.: 1023731); and Xolair (Omalizu-
mab, Genentech/Novartis, Ch.B.: S0053). The remaining 24
mAbs of the antibody collection stem from Roche and are human
or humanized IgG1 or IgG4 antibodies.
Generation of samples with induced degradation
All 37 therapeutic mAbs were subjected to induced degradation
(stressed samples). To this end, 2 mg of each antibody were
dialyzed over night at 4 uC into dilution buffer (20 mM histidine-
chloride, pH 6.0) in D-Tube Dialyzers (Novagen, MWCO 6–
8 kDa). Concentrations were determined by UV280 absorption
and adjusted to 5 mg/ml with dilution buffer. After sterile
filtration (Pall Nanosep MF, 0.2 mm) and transfer to sterile screw
cap tubes, all mAb samples were quiescently incubated for 2 weeks
at 40 uC.
mAb sample preparation for tryptic peptide mapping
experiments
80 mg of mAb reference and stressed sample were denatured
and reduced for 1 h in a final volume of 124.5 mL of 100 mM
Tris, 5.6 M guanidinium hydrochloride, 10 mM TCEP (tris(2-
carboxyethyl)phosphine, Pierce Protein Biology Products, Thermo
Fisher Scientific, Waltham, MA, USA), pH 6.0 at 37 uC. Buffer
was exchanged to 20 mM histidine chloride, 0.5 mM TCEP,
pH 6.0 in 0.5 ml Zeba Spin Desalting Columns (Pierce Protein
Biology Products, Thermo Fisher Scientific, Waltham, MA, USA).
mAbs were digested overnight at 37 uC by addition of 0.05 mg
trypsin (Promega, Madison) per mg protein in a final volume of
140 mL. Digestion was stopped by addition of 7 mL of 10% formic
acid (FA) solution, and samples were frozen at 280uC until further
analysis.
Detection of modified peptides by liquid-
chromatography tandem mass-spectrometry
14 mg of digested protein were applied to an RP-HPLC (Agilent
1100 Cap LC, Agilent Technologies, Böblingen, Germany) on a
Varian Polaris 3 C18 – Ether column (16250 mm; 3 mm particle
diameter, 180 Å pore size) from Varian (Darmstadt, Germany) for
separation. The mAb2, mAb14, and Nimotuzumab digest were
additionally separated by RP-UPLC (ACQUITY BEH300 C18
column, 16150 mm, 1.7 mm bead size, 300 Å pore size, Waters,
Manchester, UK). The HPLC or UPLC eluate was split using
Triversa NanoMate (Advion, Ithaca, NY, USA) and 380 nl/min
were infused into a LTQ Orbitrap classic tandem mass
spectrometer (Thermo Fisher Scientific, Waltham, MA, USA)
operating in positive ion mode. The mobile phases of RP-HPLC
consisted of 0.1% FA in water (solvent A) and 0.1% FA in
acetonitrile (solvent B). The HPLC was carried out using a
stepwise gradient starting at 2% solvent B, elevated to 15% from
min 5-15, to 32% from min 15-70, to 38% from min 70-80, to
100% from min 80-90, and finally dropped to 2% from min 92–
110 with a flow rate of 60 mL/min. UPLC was effected with a
linear gradient from 1 to 40% solvent B from 0 to 130 min. UV
absorption was measured at wavelengths of 220 and 280 nm. Data
acquisition was controlled by Xcalibur software (Thermo Fisher
Scientific, Waltham, MA, USA). Parameters for MS detection
were adjusted according to general experience available from
peptide analyses of recombinant antibodies. For MS/MS
measurements, fragmentation was induced by low-energy CID
using helium as a collision gas with 35% collision energy in the
LTQ. To obtain higher resolution of the fragment ions for mAb14
and Nimotuzumab, the fragmentation was performed in the
Orbitrap using a parent mass list, an isolation width of 3, a parent
mass width of 0.2 Da, AGC Target 400000, and acquisition time
of 5000 ms.
mAb14 and Nimotuzumab sample preparation for MS/
MS evaluation
For further characterization, mAb14 and Nimotuzumab
stressed samples were treated as follows. 250 mg of mAb was
denatured by addition of denaturing buffer (0.4 M Tris (Sigma-
Aldrich, Taufkirchen, Germany), 8 M guanidinium hydrochloride
(Sigma-Aldrich, Taufkirchen, Germany), pH 8) to a final volume
of 240 mL. Reduction was achieved by addition of 20 mL of
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0.24 M dithiothreitol (DTT) (Roche, Mannheim, Germany)
freshly prepared in denaturing buffer and incubation at 37 uC
for 60 min. Subsequently, the sample was alkylated by addition of
20 mL of 0.6 M iodoacetic acid (Merck, Darmstadt, Germany) in
water for 15 min at room temperature in the dark. The excess of
alkylation reagent was inactivated by addition of 30 mL of DTT
solution. The samples were then buffer exchanged to approxi-
mately 480 mL of 50 mM Tris/HCl, pH 7.5 using NAP5
Sephadex G-25 DNA grade columns (GE Healthcare, Germany).
The mAbs were digested 5 h at 37 uC by addition of 0.03 mg
trypsin (Promega, Madison) per mg protein in a final volume of
500 mL. Digestion was stopped by addition of 20 mL of 10%
formic acid (FA)-solution, and samples were frozen at 280uC until
further analysis.
Data analysis for the quantification of modification levels
SIEVE software version 2.0 (VAST Scientific Inc., Cambridge,
MA) was used to pre-filter data for differences between stressed
and reference samples. Crucial SIEVE settings were a frame time
width of 1.0 min, m/z width of 8.0 ppm, and an intensity
threshold of 50000 counts. SIEVE data filtered for monoisotopic
masses (prelement = 0) was imported into a macro-enabled Excel
workbook as well as data from in silico tryptic digestion of mAbs’
heavy and light chains, containing theoretical mass-to-charge
ratios of modified and unmodified peptides (in-house data
processing software). Differences in signal intensities or retention
time (reference vs. stress) of relevant m/z values of peptides were
detected in a semi-automatized fashion by a macro-enabled
EXCEL workbook (Microsoft, Redmond, WA, USA). The
resulting pre-filtered peptides from 76 peptide maps were
manually inspected to verify Asn and Asp modifications by their
m/z-values within the experimental mass spectrum. For quantifi-
cation, extracted ion chromatograms (XICs) of peptides of interest
were generated on the basis of their monoisotopic mass and
detected charge states using Xcalibur Software (Thermo Fisher
Scientific, Waltham, MA, USA). Relative amounts of modified vs.
unmodified peptides were calculated after manual integration of
the corresponding peak areas. Additionally, all peptides lying in
the CDR regions containing a putative hotspot motif (Asn-Gly,
Asn-Thr, Asn-Ser, Asn-Asn, Asp-Gly, Asp-Thr, Asp-Ser, Asp-Asp,
Asp-His) were analyzed even if not alerted after SIEVE software
analysis to ensure completeness of the data.
Homology modeling and extraction of 2 and 3-
dimensional parameters
Homology models were built with an automated software script
for the program MODELER 9v7 [92]. Modeling templates were
chosen based on sequence conservation from a reference structure
database consisting of human, mouse, and chimeric antibody Fab
fragment crystal structures with a minimum resolution of 2.8 Å,
and without missing internal residues in their variable regions. The
best resulting model for each mAb was used as a basis for a loop
refinement procedure (LOOPER, [85]) [93]. In turn, the 5 most
likely solutions from loop refinement were selected and used as an
ensemble of structures for each mAb. Parameters were extracted
computationally from these homology model ensembles (Table
S1). The pKa value was calculated using the program PROPKA as
part of pdb2pqr [87]. The secondary structure elements (sheet,
helix, turn, coil) were extracted with a custom script using
Discovery Studio [85]. The parameters ‘‘next different N-terminal
secondary structure’’, ‘‘next different C-terminal secondary
structure’’ and ‘‘position in coil’’ were deduced from the secondary
structure information of surrounding residues using Boolean rules
(Table S1) implemented in Pipeline Pilot [90]. A ‘‘margin’’
‘‘position in coil’’ is assigned if the next different secondary
structure element is one or two residues away, either in N- or C-
terminal direction. A ‘‘center’’ ‘‘position in coil’’ is assigned if in
both N- and C-terminal direction the secondary structure is the
same for 4 residues or in both directions for more than 4 residues.
The parameter ‘‘Fab location’’ is a number that was deduced from
combined Chothia and Kabath CDR definitions for antibodies
[94]. ‘‘Fab location’’ number 1 corresponds to framework 1 of the
heavy chain (FR H1), 2 to CDR H 1, 3 to FR H 2, 4 to CDR H 2,
5 to FR H 3, 6 to CDR H 3, 7 to FR H 4, 8 to framework 1 of the
light chain (FR L1), 9 to CDR L 1, 10 to FR L 2, 11 to CDR L 2,
12 to FR L 3, 13 to CDR L 3, and 14 to FR L 4. ‘‘CDR loop’’ is a
number ranging from 1 to 3, equal for light and heavy chain.
‘‘Successor size’’ is the solvent accessible surface area of a fully
exposed amino acid[95] in Å2 and is defined as follows: Ala, 64.78;
Cys, 95.24; Asp, 110.21; Glu, 143.92; Phe, 186.7; Gly, 23.13; His,
146.45; Ile, 151.24; Lys, 177.37; Leu, 139.52; Met, 164.67; Asn,
113.19; Pro, 111.53; Gln, 147.86; Arg, 210.02; Ser, 81.22; Thr,
111.6; Val, 124.24; Trp, 229.62; Tyr, 200.31. Terminal residues
(lacking phi and psi) are marked in our data collection. All other
parameters were extracted from the PDB files with self-written
python scripts in PyMOL [96](Table S1).
Machine learning algorithms used for classification
assessment
In order to find the best possible classifier, several different
binary classification methods that appeared suitable for this type of
classification problem, were tested, namely support vector
machines, recursive partitioning algorithms, regularized discrim-
inant analysis and neuronal networks. They were available as
packages for the statistical software R or in Pipeline Pilot [90].
Support vector machines (SVM) offer different ways to transform a
given data set into higher dimensions with the help of a so called
kernel function. Here, the svm method [97] from the package
e1071 and the ksvm method from the kernlab package [98] were
used. Recursive partitioning methods identify parameters in a step-
wise manner to split the given data set into subsets, thereby
producing a decision tree. The difference between the algorithms
is mainly based on different methods to decide on the best splitting
parameter in a given step. The ‘‘tree’’ [99] and ‘‘rpart’’ [100]
methods were used in R whereby several different splitting
methods were tested, as well as the recursive partitioning tree
implementation in Pipeline Pilot.
A more generalized form of classifier can be achieved by
combining decision trees based upon subsets of the original
training set into a so-called random forest. Regularized discrim-
inant analysis builds a classifier by combining a subset of the
available parameters using regularized group covariance matrices
in order to achieve best possible discrimination. This method is
implemented as the function ‘‘rda’’ in the klaR package [101]. A
neural network tries to emulate the basic functionality of one or
several interconnected layers of neurons. A so-called single-
hidden-layer neural network as implemented in the ‘‘nnet’’
method of R [102] was applied. Finally, a naı̈ve Bayes classifier,
a probabilistic method that uses Bayes’ theorem to compute
probabilities of a data sample belonging to a certain class, given
the training data, was tested as implemented in the ‘‘NaiveBayes’’
method of R.
As a highly imbalanced dataset with very few hotspots but many
non-hotspots had to be dealt with, class weights were introduced to
put more emphasis on the minority class. A standard weighting
scheme was identified, using the inverse of the class frequency, as
the best in terms of classification error with special emphasis on the
false negative rate.
Structure-Based Asn and Asp Degradation Prediction
PLOS ONE | www.plosone.org 10 June 2014 | Volume 9 | Issue 6 | e100736
Classification evaluation
We used a receiver operating characteristic (ROC) analysis that
is commonly applied to illustrate the performance of binary
classification systems. Hereby, the fraction of true positives out of
the positives (true positive rate, TPR) is plotted against the fraction
of false positives out of the negatives (false positive rate, FPR).
Weighting a high true-positive rate as the most important
criterion, the Pipeline Pilot implementation of a single-tree
lookahead-enabled recursive partitioning algorithm [90] was
chosen as the most suitable classifier (Figure 4). At each step, the
recursive partitioning algorithm determines a parameter and a
threshold value that is the best in splitting the dataset into
homogeneous subsets belonging to one class (hotspot or non-
hotspot). The splitting point is called a node, and the class is called
a leaf. The integrated lookahead functionality ensures that the
chosen splitting parameter and threshold value is not only optimal
for the given step but also for subsequent steps. Like this, the
model identifies the most crucial parameters for distinguishing
hotspots from non-hotspots. This classifier yields the best
combination of a high TPR, a low FPR for prediction of Asn
and Asp degradation propensity, and good algorithm interpret-
ability, even after the following optimization procedure for
prediction purposes.
The Asn and Asp single-tree lookahead-enabled recursive
partitioning algorithms were optimized in order to enhance model
performance for new data and to avoid over-fitting. Therefore,
Asn and Asp trees were pruned, i.e. branches were systematically
removed to yield smaller trees. To test the pruned models’
predictivity, they were validated against a 25% test set in forty
independent runs (Figure 5). Final Asn and Asp algorithms were
trained with 100% of the data, and were chosen on the basis of the
corresponding ROC plots (Figure 4) as well as meaningful tree
interpretability. A lookahead depth of 4 with 7 lookahead
alternatives and pruning level 4 were used. They are represented
as decision trees in Figure 6.
Recursive partitioning and prediction
Terminal residues as well as residues with less than 3%
modification rate in the stressed sample (weak spots and reactive
spots) were excluded from the training. All 20 parameters
described were supplied to the training set. A main feature of
the single-tree recursive partitioning classification algorithm in
Pipeline Pilot is the opportunity to assign a certain ‘‘look-ahead’’
depth that allows for better classification due to testing more
alternative splits.
The two resulting prediction models are applied to new data.
The programmed rule for a hotspot alert is the following: if at least
one Asn/Asp in a set of five homology models is predicted to be a
hotspot, the residue per se is classified as such. The probability for
hotspot classification can range from a 0.5 minimum to a 1.0
maximum for each member of the ensemble. Thus, prediction
output is not only qualitative but also quantitative, expressed in the
average of the probabilities of each member for being a hotspot
including the standard deviation. Like this, the information if one,
two, three, four, or five members of the ensemble are in hotspot
conformation, is contained in the prediction output.
Supporting Information
Figure S1 Example of extracted ion current chromato-
grams and tandem mass spectra for detection and
localization of a deamidated peptide. A. Extracted ion
current chromatograms of the unmodified tryptic peptide
SINSATHYAESVK at m/z 703.84 and 469.56 (charges 2+ and
3+, upper panel) and its deamidated form at m/z 704.34 and
469.89 (charges 2+ and 3+, lower panel). Deamidation corre-
sponds to a mass increase of 0.98 Da. The unmodified peptide
elutes at 18.4 min. The deamidated species (peak 1 and 2) are
eluting at 18.7, and 19.2 min B. y+ fragment ions of the
deamidated peptide SINSATHYAESVK and their theoretical
masses (m/z) C. MS2 spectrum of the unmodified peptide at m/z
703.84 (charge 2+) and the deamidated peptide at m/z 704.34
(charge 2+). The y+ fragment ions supporting the deamidation of
the Asn-Ser motif compared to the unmodified peptide were
detected in the LTQ D. Zoom into y fragment ions 10 and 11.
The deamidation-induced y10
+ shift is indicated by a red arrow.
(TIF)
Figure S2 Conformational flexibility of loops is cap-
tured by use of 5 homology modeling solutions. The 5
most likely solutions of the loop refinement procedure are
structurally superimposed. For illustration purposes, only the side
chains of the CDR H3 are shown as lines and in different colors
per model.
(TIF)
Table S1 Weak spots which were excluded from the
training dataset because the extent of modification
(.1.0 and ,3.0% after stress) is detectable but consid-
ered irrelevant for stability under real-time storage
conditions.
(DOCX)
Table S2 Reactive spots which were excluded from the
training dataset because the extent of modification
(,1.0% after stress) is detectable but considered
irrelevant for stability under real-time storage condi-
tions.
(DOCX)
Table S3 Comparison of the various classifiers. Abbre-
viations and data origins are analogous to Figure 4.
(DOCX)
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